Format

Send to

Choose Destination

Gadofosveset-enhanced magnetic resonance angiography.

Author information

1
University Medical Center Hamburg-Eppendorf, Hamburg, Germany. goyen@uke.de

Abstract

Gadofosveset (Vasovist, Bayer Schering Pharma AG, Berlin/Germany) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds to albumin providing extended intravascular enhancement compared wth existing extracellular magnetic resonance contrast agents. Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds.

KEYWORDS:

Vasovist®; gadofosveset; magnetic resonance angiography (MRA); magnetic resonance contrast agent; magnetic resonance imaging

PMID:
18629367
PMCID:
PMC2464762
DOI:
10.2147/vhrm.2008.04.01.1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center